Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts
Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.
PharmiWeb7h
Advancing the development of CRISPR platform technologies
Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.
STAT3h
Chinese biotech says it will start first in vivo beta-thalassemia trial
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Vertex Pharmaceuticals' SWOT analysis: stock outlook amid pipeline progress
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...
PharmiWeb2h
Phacilitate Awards Katherine High with the 2025 Lifetime Achievement Award at the Advanced Therapies Awards Ceremony in Dallas
Phacilitate, a leading brand that connects advanced therapies industry leaders through inspiring conferences, vibrant communities and market intelligence, today presented Katherine A. High, M.D. with ...